Total Payments
$25,362
2024 Payments
$1,455
Companies
40
Transactions
529
Medicare Patients
9,167
Medicare Billing
$1.0M
Payment Breakdown by Category
Other$12,000 (47.3%)
Food & Beverage$11,867 (46.8%)
Travel$776.06 (3.1%)
Consulting$600.00 (2.4%)
Education$118.66 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,000 | 4 | 47.3% |
| Food and Beverage | $11,867 | 516 | 46.8% |
| Travel and Lodging | $776.06 | 2 | 3.1% |
| Consulting Fee | $600.00 | 2 | 2.4% |
| Education | $118.66 | 5 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boston Scientific Corporation | $14,178 | 30 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,480 | 90 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,121 | 52 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,066 | 43 | $0 (2024) |
| Amgen Inc. | $996.75 | 45 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $811.92 | 37 | $0 (2023) |
| Abbott Laboratories | $660.56 | 18 | $0 (2024) |
| Merck Sharp & Dohme LLC | $594.77 | 21 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $485.01 | 27 | $0 (2024) |
| Novo Nordisk Inc | $455.38 | 23 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,455 | 68 | Boehringer Ingelheim Pharmaceuticals, Inc. ($243.54) |
| 2023 | $2,124 | 121 | Amgen Inc. ($331.77) |
| 2022 | $1,863 | 97 | Boehringer Ingelheim Pharmaceuticals, Inc. ($298.63) |
| 2021 | $1,004 | 36 | Abbott Laboratories ($330.62) |
| 2020 | $524.59 | 22 | E.R. Squibb & Sons, L.L.C. ($110.22) |
| 2019 | $4,269 | 56 | Boston Scientific Corporation ($3,280) |
| 2018 | $7,765 | 64 | BOSTON SCIENTIFIC CORPORATION ($6,263) |
| 2017 | $6,355 | 65 | BOSTON SCIENTIFIC CORPORATION ($4,234) |
All Payment Transactions
529 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $20.69 | General |
| Category: Cardiology | ||||||
| 12/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: DIABETES | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $16.69 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/10/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $21.71 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 12/04/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $11.26 | General |
| 11/21/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/20/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $21.51 | General |
| Category: Cardiovascular | ||||||
| 11/19/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $22.48 | General |
| 11/14/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $22.94 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/12/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $23.82 | General |
| 11/07/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Food and Beverage | In-kind items and services | $31.89 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 10/29/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $15.76 | General |
| Category: Cardiovascular | ||||||
| 10/23/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $20.94 | General |
| Category: Cardiology | ||||||
| 10/22/2024 | Celgene Corporation | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $20.05 | General |
| Category: Cardiovascular | ||||||
| 10/15/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $30.45 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 10/10/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $22.88 | General |
| 10/08/2024 | Abbott Laboratories | JOT DX (Device) | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: Cardiac Rhythm Management | ||||||
| 09/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.30 | General |
| Category: DIABETES | ||||||
| 08/21/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.02 | General |
| Category: DIABETES | ||||||
| 08/20/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $14.28 | General |
| Category: Cardiovascular | ||||||
| 08/16/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $18.98 | General |
| Category: Cardiology | ||||||
| 08/16/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $17.76 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/15/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $24.24 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/14/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $24.15 | General |
| 08/09/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $19.71 | General |
| Category: Cardiology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 32 | 2,826 | 4,598 | $2.1M | $324,810 |
| 2022 | 28 | 3,095 | 4,477 | $1.8M | $309,484 |
| 2021 | 23 | 1,577 | 2,809 | $1.3M | $264,540 |
| 2020 | 20 | 1,669 | 2,086 | $431,677 | $106,541 |
Total Patients
9,167
Total Services
13,970
Medicare Billing
$1.0M
Procedure Codes
108
All Medicare Procedures & Services
108 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 399 | 854 | $452,620 | $95,737 | 21.2% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 104 | 104 | $411,840 | $43,468 | 10.6% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 146 | 156 | $276,120 | $27,491 | 10.0% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 104 | 206 | $114,860 | $20,002 | 17.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 99 | 259 | $75,110 | $19,136 | 25.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 103 | 105 | $56,700 | $12,319 | 21.7% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 68 | 272 | $27,472 | $11,966 | 43.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 83 | 83 | $54,780 | $11,826 | 21.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 49 | 60 | $44,400 | $10,083 | 22.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 413 | 684 | $61,560 | $9,030 | 14.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 149 | 154 | $60,970 | $8,961 | 14.7% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 26 | 131 | $155,890 | $8,755 | 5.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 31 | 31 | $25,830 | $6,063 | 23.5% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 104 | 104 | $39,520 | $6,058 | 15.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 15 | 24 | $24,480 | $4,833 | 19.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 29 | $23,200 | $4,576 | 19.7% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 424 | 575 | $34,500 | $4,040 | 11.7% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2023 | 22 | 129 | $20,640 | $2,899 | 14.0% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 48 | 120 | $24,000 | $2,573 | 10.7% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 37 | 95 | $19,950 | $2,469 | 12.4% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 36 | 36 | $24,840 | $2,289 | 9.2% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 11 | 11 | $14,960 | $2,221 | 14.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 13 | $5,710 | $1,445 | 25.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 115 | 158 | $4,170 | $1,327 | 31.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 17 | 17 | $6,460 | $1,233 | 19.1% |
About Dr. Ari Paley, M.D
Dr. Ari Paley, M.D is a Cardiovascular Disease healthcare provider based in Scarsdale, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/27/2007. The National Provider Identifier (NPI) number assigned to this provider is 1386834133.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ari Paley, M.D has received a total of $25,362 in payments from pharmaceutical and medical device companies, with $1,455 received in 2024. These payments were reported across 529 transactions from 40 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($12,000).
As a Medicare-enrolled provider, Paley has provided services to 9,167 Medicare beneficiaries, totaling 13,970 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 108 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Cardiovascular Disease
- Location Scarsdale, NY
- Active Since 07/27/2007
- Last Updated 03/10/2023
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1386834133
Products in Payments
- WATCHMAN (Device) $13,893
- ELIQUIS (Drug) $1,176
- ENTRESTO (Drug) $1,172
- JARDIANCE (Drug) $1,028
- XARELTO (Drug) $892.16
- Repatha (Biological) $816.29
- VERQUVO (Drug) $357.56
- CAMZYOS (Drug) $337.83
- LEQVIO (Drug) $307.92
- Reveal LINQ (Device) $241.78
- WATCHMAN Access System (Device) $223.98
- ZEPATIER (Drug) $180.44
- BRILINTA (Drug) $177.97
- Ozempic (Drug) $174.00
- MitraClip System (Device) $165.86
- HeartMate 3 Left Ventricular Assist Device (Device) $164.76
- Corlanor (Drug) $162.58
- Vascepa (Drug) $159.47
- FUROSCIX (Drug) $159.23
- FARXIGA (Drug) $153.70
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Scarsdale
Dr. Daniel Lerner, M.d, M.D
Cardiovascular Disease — Payments: $470,860
Cardiovascular Disease $470,860
Dr. Srirama Kalapatapu, M.d, M.D
Cardiovascular Disease — Payments: $185,044
Cardiovascular Disease $185,044
Dr. Anthony Mercando, Md, MD
Cardiovascular Disease — Payments: $69,054
Cardiovascular Disease $69,054
Dr. Sanjay Naik, M.d, M.D
Cardiovascular Disease — Payments: $23,287
Cardiovascular Disease $23,287
Dr. Amit Chhabra, M.d, M.D
Cardiovascular Disease — Payments: $16,979
Cardiovascular Disease $16,979
Dr. Howard Chester, M.d, M.D
Cardiovascular Disease — Payments: $2,207
Cardiovascular Disease $2,207